Compare PGY & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PGY | DNTH |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | N/A | N/A |
| Metric | PGY | DNTH |
|---|---|---|
| Price | $21.85 | $41.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $39.86 | ★ $68.00 |
| AVG Volume (30 Days) | ★ 2.5M | 678.9K |
| Earning Date | 02-12-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,245,946,000.00 | $3,078,000.00 |
| Revenue This Year | $28.75 | N/A |
| Revenue Next Year | $17.23 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 28.33 | N/A |
| 52 Week Low | $8.27 | $13.37 |
| 52 Week High | $44.99 | $45.46 |
| Indicator | PGY | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 40.60 | 51.40 |
| Support Level | $22.72 | $42.02 |
| Resistance Level | $24.06 | $44.00 |
| Average True Range (ATR) | 1.31 | 1.80 |
| MACD | 0.01 | -0.28 |
| Stochastic Oscillator | 16.63 | 42.45 |
Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.